Insulet — May 8, 2025 release

1 Compared to people using multiple daily injections with a continuous glucose monitor, Omnipod 5 demonstrated an average reduction in HbA1c of -0.8% and an average of 5.4 hours more per day with glucose levels in the target range without an increase in hypoglycemia 2 • Successfully issued $450 million senior unsecured notes and upsized and extended the maturity of revolving credit facility. Extinguished $420 million principal of convertible notes to date • Board of Directors authorized a program to repurchase up to $125 million of common stock through December 31, 2026 to offset dilution from stock-based compensation 2025 Outlook: For the quarter ending June 30, 2025 and year ending December 31, 2025, the Company is providing the following guidance (revenue in constant currency): Q2 2025 Guidance FY 2025 Guidance (as of 5/8/2025) FY 2025 Prior Guidance (as of 2/20/2025) U.S. Omnipod 22% - 25% 18% - 21% 16% - 20% International Omnipod 27% - 30% 27% - 30% 22% - 26% Total Omnipod 23% - 26% 20% - 23% 17% - 21% Drug Delivery 10% - 15% (35)% - (25)% (55)% - (45)% Total 23% - 26% 19% - 22% 16% - 20% Gross Margin ~71% ~70.5% Adjusted Operating Margin ~16.5% ~16.5% Conference Call: Insulet will host a conference call at 4:30 p.m. (Eastern Time) on May 8, 2025 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquar